clinical trial on the efficacy of Raloxifene on disease activity in Rheumatoid Arthritis
Not Applicable
Completed
- Conditions
- Rheumatoid Arthritis.Rheumatoid arthritis, unspecified
- Registration Number
- IRCT2015052022334N1
- Lead Sponsor
- Research Chancellor of Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Patients should be selected from postmenopausal women;Patients should fulfill at least 4 criteria of ACR-1987 for Rheumatoid Arthritis;Patients should have DAS28-ESR in range of 2.5-5.5.
Exclusion criteria: Patients with thromboembolic events;Patients with other rheumatologic disorders;Patients with severe postmenopausal symptoms;Patients with known psychological disorders
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease activity of rheumatoid arthritis. Timepoint: monthly in first 3 month, every 2 months since 5th month. Method of measurement: based on DAS28-ESR formula.;Complications of Raloxifene. Timepoint: monthly in first 3 month, every 2 months since 5th month. Method of measurement: questionare.
- Secondary Outcome Measures
Name Time Method Bone mineral density. Timepoint: in the begining and end of the study. Method of measurement: Total BMD test.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Raloxifene's effect on rheumatoid arthritis disease activity in postmenopausal women?
How does Raloxifene compare to standard-of-care therapies for managing glucocorticoid-induced osteoporosis in rheumatoid arthritis patients?
Which biomarkers are associated with response prediction to Raloxifene in postmenopausal rheumatoid arthritis patients with osteoporosis?
What are the potential adverse events of Raloxifene in postmenopausal women with rheumatoid arthritis and how are they managed?
Are there combination therapies involving Raloxifene that enhance outcomes for glucocorticoid-induced osteoporosis in rheumatoid arthritis patients?